AIM: To investigate the feasibility of separation and cultivation of circulating tumor cells (CTCs) in pancreatic cancer (PaC) using a filtration device. METHODS: In total, 24 PaC patients who were candidates for surgical treatment were enrolled into the study. Peripheral blood samples were collected before an indicated surgery. For each patient, approximately 8 mL of venous blood was drawn from the antecubital veins. A new size-based separation MetaCell technology was used for enrichment and cultivation of CTCs in vitro. (Separated CTCs were cultured on a membrane in FBS enriched RPMI media and observed by inverted microscope. The cultured cells were analyzed by means of histochemistry and immunohistochemistry using the specific antibodies to identify the cell origin. RESULTS: CTCs were detected in 16 patients (66.7%) of the 24 evaluable patients. The CTC positivity did not reflect the disease stage, tumor size, or lymph node involvement. The same percentage of CTC positivity was observed in the metastatic and non-metastatic patients (66.7% vs 66.7%). We report a successful isolation of CTCs in PaC patients capturing proliferating cells. The cells were captured by a capillary action driven size-based filtration approach that enabled cells cultures from the viable CTCs to be unaffected by any antibodies or lysing solutions. The captured cancer cells displayed plasticity which enabled some cells to invade the separating membrane. Further, the cancer cells in the "bottom fraction", may represent a more invasive CTC-fraction. The CTCs were cultured in vitro for further downstream applications. CONCLUSION: The presented size-based filtration method enables culture of CTCs in vitro for possible downstream applications.
AIM: To investigate the feasibility of separation and cultivation of circulating tumor cells (CTCs) in pancreatic cancer (PaC) using a filtration device. METHODS: In total, 24 PaC patients who were candidates for surgical treatment were enrolled into the study. Peripheral blood samples were collected before an indicated surgery. For each patient, approximately 8 mL of venous blood was drawn from the antecubital veins. A new size-based separation MetaCell technology was used for enrichment and cultivation of CTCs in vitro. (Separated CTCs were cultured on a membrane in FBS enriched RPMI media and observed by inverted microscope. The cultured cells were analyzed by means of histochemistry and immunohistochemistry using the specific antibodies to identify the cell origin. RESULTS: CTCs were detected in 16 patients (66.7%) of the 24 evaluable patients. The CTC positivity did not reflect the disease stage, tumor size, or lymph node involvement. The same percentage of CTC positivity was observed in the metastatic and non-metastatic patients (66.7% vs 66.7%). We report a successful isolation of CTCs in PaC patients capturing proliferating cells. The cells were captured by a capillary action driven size-based filtration approach that enabled cells cultures from the viable CTCs to be unaffected by any antibodies or lysing solutions. The captured cancer cells displayed plasticity which enabled some cells to invade the separating membrane. Further, the cancer cells in the "bottom fraction", may represent a more invasive CTC-fraction. The CTCs were cultured in vitro for further downstream applications. CONCLUSION: The presented size-based filtration method enables culture of CTCs in vitro for possible downstream applications.
Entities:
Keywords:
Biomarker; Circulating tumor cells; Cultivation; Pancreatic cancer
Authors: Maria T Sandri; Laura Zorzino; Maria C Cassatella; Fabio Bassi; Alberto Luini; Chiara Casadio; Edoardo Botteri; Nicole Rotmensz; Laura Adamoli; Franco Nolè Journal: Ann Surg Oncol Date: 2010-02-05 Impact factor: 5.344
Authors: F Farace; C Massard; N Vimond; F Drusch; N Jacques; F Billiot; A Laplanche; A Chauchereau; L Lacroix; D Planchard; S Le Moulec; F André; K Fizazi; J C Soria; P Vielh Journal: Br J Cancer Date: 2011-08-09 Impact factor: 7.640
Authors: L Khoja; A Backen; R Sloane; L Menasce; D Ryder; M Krebs; R Board; G Clack; A Hughes; F Blackhall; J W Valle; C Dive Journal: Br J Cancer Date: 2011-12-20 Impact factor: 7.640
Authors: Marian Liberko; Katarina Kolostova; Arpad Szabo; Robert Gurlich; Martin Oliverius; Renata Soumarova Journal: In Vivo Date: 2021 Jan-Feb Impact factor: 2.155
Authors: Colin M Court; Jacob S Ankeny; Shuang Hou; Hsian-Rong Tseng; James S Tomlinson Journal: Expert Rev Mol Diagn Date: 2015-09-21 Impact factor: 5.225
Authors: Birte Kulemann; Andrew S Liss; Andrew L Warshaw; Sindy Seifert; Peter Bronsert; Torben Glatz; Martha B Pitman; Jens Hoeppner Journal: Tumour Biol Date: 2015-12-18
Authors: Heming Li; Qing H Meng; Hyangsoon Noh; Izhar Singh Batth; Neeta Somaiah; Keila E Torres; Xueqing Xia; Ruoyu Wang; Shulin Li Journal: Cancer Lett Date: 2017-06-23 Impact factor: 8.679
Authors: Melody J Xu; Jay F Dorsey; Ravi Amaravadi; Giorgos Karakousis; Charles B Simone; Xiaowei Xu; Wei Xu; Erica L Carpenter; Lynn Schuchter; Gary D Kao Journal: Oncologist Date: 2015-11-27
Authors: Katarina Kolostova; Adam Rzechonek; Jan Schützner; Robert Grill; Robert Lischke; Pavel Hladik; Jan Simonek; Vladimir Bobek Journal: In Vivo Date: 2017 Nov-Dec Impact factor: 2.155